Literature DB >> 10979900

Effects of intermittent interleukin-2 therapy on plasma and tissue human immunodeficiency virus levels and quasi-species expression.

J A Kovacs1, H Imamichi, S Vogel, J A Metcalf, R L Dewar, M Baseler, R Stevens, J Adelsberger, L Lambert, R T Davey, R E Walker, J Falloon, M A Polis, H Masur, H C Lane.   

Abstract

To characterize the effects of intermittent interleukin (IL)-2 therapy on human immunodeficiency virus (HIV), 11 patients underwent detailed virological evaluation during a year of IL-2 therapy. Six patients showed a >0.5 log increase in plasma HIV during at least 1 IL-2 cycle, with 2 experiencing an increase in >50% of cycles. Three of the remaining 5 patients had a >0.5 log decrease during at least 1 IL-2 cycle, and the remaining patients exhibited <0.5 log changes. No changes in lymphoid (tonsil) levels of HIV were seen during the year. Quasi-species analysis in a separate cohort demonstrated that the virus induced by IL-2 most commonly resembled pre-IL-2 plasma quasi species. Thus, intermittent IL-2 does not result in sustained increases in either plasma or tissue levels of HIV and does not result in sustained expression of a previously silent quasi species.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10979900     DOI: 10.1086/315821

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  4 in total

1.  Immune Reconstitution Strategies in HIV.

Authors:  Matthew R. Leibowitz; Ronald T. Mitsuyasu
Journal:  Curr Infect Dis Rep       Date:  2001-06       Impact factor: 3.725

2.  Predictors of bacterial pneumonia in Evaluation of Subcutaneous Interleukin-2 in a Randomized International Trial (ESPRIT).

Authors:  S L Pett; C Carey; E Lin; D Wentworth; J Lazovski; J M Miró; F Gordin; B Angus; M Rodriguez-Barradas; R Rubio; G Tambussi; D A Cooper; S Emery
Journal:  HIV Med       Date:  2010-08-31       Impact factor: 3.180

3.  IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection.

Authors:  Irini Sereti; Richard M Dunham; John Spritzler; Evgenia Aga; Michael A Proschan; Kathy Medvik; Catherine A Battaglia; Alan L Landay; Savita Pahwa; Margaret A Fischl; David M Asmuth; Allan R Tenorio; John D Altman; Lawrence Fox; Susan Moir; Angela Malaspina; Michel Morre; Renaud Buffet; Guido Silvestri; Michael M Lederman
Journal:  Blood       Date:  2009-04-20       Impact factor: 22.113

4.  Long-term effects of intermittent IL-2 in HIV infection: extended follow-up of the INSIGHT STALWART Study.

Authors:  Norman Markowitz; Gustavo Lopardo; Deborah Wentworth; Daniela Gey; Abdel Babiker; Lawrence Fox; Jorge Tavel
Journal:  PLoS One       Date:  2012-10-17       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.